Chemically augmented malaria sporozoites display an altered immunogenic profile.
adjuvant
immunogenicity
malaria
supramolecular chemistry
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
04
2023
accepted:
25
07
2023
medline:
19
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Despite promising results in malaria-naïve individuals, whole sporozoite (SPZ) vaccine efficacy in malaria-endemic settings has been suboptimal. Vaccine hypo-responsiveness due to previous malaria exposure has been posited as responsible, indicating the need for SPZ vaccines of increased immunogenicity. To this end, we here demonstrate a proof-of-concept for altering SPZ immunogenicity, where supramolecular chemistry enables chemical augmentation of the parasite surface with a TLR7 agonist-based adjuvant (SPZ-SAS(CL307)).
Identifiants
pubmed: 37720224
doi: 10.3389/fimmu.2023.1204606
pmc: PMC10500441
doi:
Substances chimiques
Malaria Vaccines
0
Adjuvants, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1204606Informations de copyright
Copyright © 2023 Duszenko, van Schuijlenburg, Chevalley-Maurel, van Willigen, de Bes-Roeleveld, van der Wees, Naar, Baalbergen, Heieis, Bunschoten, Velders, Franke-Fayard, van Leeuwen and Roestenberg.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Vaccines (Basel). 2015 Apr 16;3(2):320-43
pubmed: 26343190
Bioconjug Chem. 2020 Nov 18;31(11):2465-2475
pubmed: 33146010
Front Immunol. 2017 Mar 09;8:212
pubmed: 28337195
J Immunol. 2013 Feb 1;190(3):1038-47
pubmed: 23264654
Curr Mol Med. 2006 Mar;6(2):169-85
pubmed: 16515509
Cell Immunol. 1999 Oct 10;197(1):62-72
pubmed: 10555997
Sci Rep. 2017 Jan 06;7:39908
pubmed: 28057918
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
J Exp Med. 2002 Mar 4;195(5):617-24
pubmed: 11877484
Vaccine. 1998 Aug-Sep;16(14-15):1391-5
pubmed: 9711777
Bioconjug Chem. 2016 Oct 19;27(10):2372-2385
pubmed: 27583777
Oncoimmunology. 2019 Apr 19;8(7):1601480
pubmed: 31143525
J Immunol. 2015 Sep 15;195(6):2710-21
pubmed: 26254338
Science. 2013 Sep 20;341(6152):1359-65
pubmed: 23929949
Front Cell Infect Microbiol. 2018 Jul 19;8:247
pubmed: 30073152
Theranostics. 2018 Mar 23;8(9):2377-2386
pubmed: 29721086
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
ACS Infect Dis. 2020 Jul 10;6(7):1734-1744
pubmed: 32364374
Nature. 2017 Feb 23;542(7642):445-449
pubmed: 28199305
PLoS Pathog. 2020 Sep 8;16(9):e1008799
pubmed: 32898164
Nat Biotechnol. 2020 Mar;38(3):320-332
pubmed: 31932728
Lancet Infect Dis. 2017 May;17(5):498-509
pubmed: 28216244
Nat Immunol. 2005 Aug;6(8):769-76
pubmed: 15995707
Nat Commun. 2013;4:2836
pubmed: 24284865
Am J Trop Med Hyg. 2019 Jun;100(6):1433-1444
pubmed: 30994090
Chembiochem. 2022 Dec 5;23(23):e202200434
pubmed: 36177993
Nat Med. 2021 Sep;27(9):1636-1645
pubmed: 34518679
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15190-4
pubmed: 16219698
Blood. 2006 Jul 15;108(2):544-50
pubmed: 16537810
J Clin Invest. 2010 Feb;120(2):607-16
pubmed: 20101095
Eur J Immunol. 2021 May;51(5):1153-1165
pubmed: 33486759
ACS Nano. 2013 May 28;7(5):3912-25
pubmed: 23590591
Nat Microbiol. 2018 Nov;3(11):1224-1233
pubmed: 30349082
Nature. 1987 Dec 17-23;330(6149):664-6
pubmed: 3120015